Bishop Hans Edgar 4

What Happened Bishop Hans Edgar, a director of Sana Biotechnology, received an award/acquisition of 7,763 shares on April 6, 2026. The Form 4 reports a reported acquisition price of $0.00 (no cash paid) — the transaction is disclosed as an award of fully vested restricted stock units (see footnote). This is a grant/compensation-type transaction rather than an open-market purchase.

Key Details

• Transaction date: 2026-04-06; Form 4 filed: 2026-04-08 (appears timely).
• Transaction type: Award/Acquisition (code A); 7,763 shares acquired at $0.00 per share (total cash paid $0).
• Footnote: F1 — Consists of fully vested restricted stock units.
• Shares owned after transaction: Not specified in the provided summary of the filing.
• No indication of a sales, 10b5-1 plan, tax withholding, or cashless exercise in the provided data.

Context Fully vested RSUs mean the shares were granted and are immediately owned by the insider (subject to any company transfer restrictions). These awards are typically part of director compensation or retention packages and do not necessarily signal a personal buy or sell decision. For a fuller picture, retail investors may want to review the insider’s total holdings and prior SEC filings to see how this award affects overall insider ownership.